Novo Nordisk Surges 9% to $606.6B Market Cap, Expands into Cell and Gene Therapy with New Pipeline Highlights

Mar 08, 2024 10:57 CST Updated 10:58

Novo Nordisk

Insulin Developer and Manufacturer

On March 7, 2024, Novo Nordisk held an Investor Day event to introduce the latest developments in its R&D pipeline.On the same day, Novo Nordisk's stock price surged by 9%, with a market value reaching $606.6 billion.

Novo Nordisk actively expands its layout in new drug formats, including siRNA, cell therapy, and gene therapy.

Recommended reading article link (click the underlined title below to open the full text):

Entering Cell Therapy! Novo Nordisk's Cell Treatment Drug HS-001 Administered to First Patient

Gene Therapy Company Freeline Completes $120 Million Financing, Novo Nordisk Ventures Joins

Novo Nordisk's RNAi Therapy Receives FDA Approval for Market Launch

Novo Nordisk Completed siRNA Therapy Layout by Acquiring Dicerna in 2021.

Core iterative products in the diabetes field,Once a monthThe GLP-1R/GIPR dual-target agonist is expected to have Phase I clinical data in 2025.

Daily oral Amycretin, a GLP-1R/amylin receptor dual agonist, successfully completes Phase I clinical trial.

Oral Amycretin treatment for 12 weeks resulted in a 13.1% weight loss, significantly surpassing the approximately 6% weight loss efficacy of semaglutide over 12 weeks.

Novo Nordisk is also developing a GLP-1R/GIPR/amylin receptor tri-agonist, which is expected to enter the clinical stage within the next year.

Diabetes Pipeline: Amycretin to Enter Phase II Clinical Trials This Year; Weekly GLP-1R/GIPR Dual Agonist Injection to Enter Phase II Clinical Trials This YearOne injection per monthGLP-1R/GIPR dual-target agonist is in Phase I clinical trials.Once Weekly Oral AdministrationSemaglutide is in Phase I clinical trials.Once a weekUltra-long-acting insulin is expected to be approved for marketing this year.

Weight Loss Pipeline as Follows:

Summary

In terms of multi-target approaches, Novo Nordisk focuses on GLP-1R, GIPR, and amylin receptors, continuously extending the injection frequency in formulations as well as developing oral alternatives. It is also the most active in expanding indications. In terms of new drug modalities, siRNA has expanded to intracellular targets, becoming another therapeutic cornerstone alongside peptides/proteins, while also advancing cell and gene therapies.

E.N.D

Previous article recommendations:

TOP10 Pharmaceutical Companies Ranking Released, All Have Invested in Cell and Gene Therapy

"Innovative Drugs" First Appeared in Government Work Report｜Accelerate the Development of Innovative Drug Industries, Actively Build New Growth Engines such as Biomanufacturing

Illustrated Guide to NK Cell Therapy

CAR-T Therapy from CoStim Pharmaceuticals Launches at 1.15 Million Yuan, with Expected Annual Sales Peak Exceeding 1 Billion Yuan

Two National Scientific Research Platforms Approved and Established by Subsidiaries of China National Pharmaceutical Group's China Biologic Products Are Officially Unveiled

FDA Lifts Clinical Hold on Iovance's TIL Cell Therapy

Differences Among CXO, CRO, CMO, CDMO, and CSO

"Biden Bill" Wind Change, CXO Soars

TIL Cell Therapy Priced at 3.7 Million Shows Promising Market Potential, with First-Quarter Sales Expected to Exceed 30 Million

Synthetic biology ranks first!

Fosun Pharma Subsidiary's NK Cell Therapy GCK-01 Approved for Clinical Trials

First in China, Yaotang Biotech's In Vivo Gene Editing Drug YOLT-201 Approved for Clinical Trials

Guangdong Province Issues New Policy! Focus on Five Major Projects: Gene Technology, Cell Therapy, AI + Biomedicine, Synthetic Biology

Six Companies in China Complete New Round of Financing, Focusing on Cell and Gene Therapy Fields

Covering an area of approximately 13,000 square meters, the Sinobio Cell Therapy Drug Industrialization Base Project has been established.

Another Global Strategic Center of a Pharmaceutical Giant Settles in Shanghai, Which Will Become an Important R&D Base in the Field of Cell Therapy

The First AAV Gene Therapy for Hemophilia A Falls Far Short of Sales Expectations Last Year

Xiong'an Officially Issues! Support for the Development of Modern Life Sciences and Biotechnology Industries such as Cell Therapy, Genetic Engineering, and Tissue Engineering

Government Invests 6 Billion Yuan to Fund the Establishment of a Life Health Research Institute, Focusing on Cutting-edge Topics such as Cell and Gene Therapy

NVIDIA CEO Jensen Huang: The Era of Having to Learn Computer Science and Programming is Over, the Next Golden Track is Life Science and Engineering

First in China: Universal CAR-NK for Treating Systemic Lupus Erythematosus Approved for Clinical Trials

Beijing to Prioritize Cell and Gene Therapy, Synthetic Biology Manufacturing, and Other Cutting-Edge Emerging Fields as Key Tasks for 2024

FDA Releases Guidelines for the Development of Gene-Edited Therapies and CAR-T Therapies (Full Text of Guidelines Attached)

CDE Releases "Technical Guiding Principles for Non-Clinical Research of Human Stem Cell Products"

CRISPR/Cas9 Gene Editing Therapy Receives FDA Approval for Treating β-Thalassemia

Disclaimer: The content of this article is sourced from Medical Notes, aiming for knowledge sharing. All content is for reference only and does not constitute any advice.